ArticleFrontiers in nutrition2026
Metabolic syndrome and risk of incident chronic pancreatitis: a prospective cohort study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: The association between metabolic syndrome (MetS) and chronic pancreatitis (CP) remains unclear. This study aimed to examine whether MetS is independently associated with an increased risk of CP. Methods: We analyzed data from 349,995 participants in the UK Biobank who were free of CP at baseline. MetS was defined according to NCEP-ATP III criteria. Incident CP cases were identified via hospital admissions and death registries using ICD codes. Cox proportional hazards models were used to estimate hazard ratios (HRs) with sequential adjustment for demographic, lifestyle, clinical, and inflammatory factors. Subgroup, nonlinear, mediation, and sensitivity analyses were performed to assess robustness. Results: Over a median follow-up of 18 years, 623 incident CP cases occurred. MetS was significantly associated with increased CP risk after full adjustment (HR 2.02, 95% CI 1.64-2.49). A clear dose-response relationship was observed between the number of MetS components and CP risk. Among individual components, hyperglycemia (HR 2.59) and elevated waist-to-hip ratio (Q4 vs. Q1 HR 2.78) were the strongest predictors. Subgroup analyses showed stronger associations in younger individuals, females, never smokers, and current drinkers. Systemic inflammation, particularly via neutrophils and CRP, mediated approximately 8 and 3% of the association, respectively. Sensitivity analyses confirmed the robustness of these findings. Conclusion: MetS is an independent risk factor for CP, with risk rising as the number of MetS components increases. Hyperglycemia and central adiposity are key drivers. Managing metabolic health may help reduce CP risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.